Abstract
Acute promyelocytic leukemia (APL) is a variant of AML characterized by t (15; 17). The
discovery of the molecular pathogenesis has led to the first targeted therapy for acute
leukemia: all-trans retinoic acid (ATRA). ATRA is usually associated to anthracycline-based
chemotherapy obtaining high response rates, but some potential longterm sequelae are
described [1]. The introduction of arsenic trioxide (ATO)[2] and ATRA was compared to
standard chemotherapy in a pivotal trial with excellent results both in terms of complete
Lingua originale | English |
---|---|
pagine (da-a) | 1330-1338 |
Numero di pagine | 9 |
Rivista | LEUKEMIA & LYMPHOMA |
Stato di pubblicazione | Pubblicato - 2019 |
Keywords
- transfusion support promyelocytic leukemia